Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports the first successful use of zanubrutinib to treat a 15-year-old Chinese girl with severe refractory Evans' syndrome, resulting in a sustained recovery of platelet counts and haemoglobin levels.

This study used machine learning to identify FDA-approved drugs afatinib, neratinib, and zanubrutinib as potential KRASG12C inhibitors for resistant non-small-cell lung cancer, highlighting the potential of AI in drug repurposing.